19 Paul Tudor Jones II ADT Trades
Paul Tudor Jones II's position in ADT is currently worth $14.6M. That's 0.11% of their equity portfolio (223rd largest holding). The first ADT trade was made in Q3 2018. Since then Paul Tudor Jones II bought shares nine more times and sold shares on nine occasions. The stake costed the investor $12.7M, netting the investor a gain of 15% so far.
Avg closing price
Price range
Increased shares by 1.0% (+16.2k shares)
Q2 2025
Avg closing price
$8.18
Price range
$7.54
-
$8.60
New holding (+1.66M shares)
Q1 2025
Avg closing price
$7.53
Price range
$6.87
-
$8.23
Sold -273k shares
Q3 2023
Avg closing price
$6.23
Price range
$5.82
-
$6.71
New holding (+273k shares)
Q2 2023
Avg closing price
$6.26
Price range
$5.13
-
$7.16
Sold -54.7k shares
Q1 2023
Avg closing price
$8.15
Price range
$6.94
-
$9.79
Increased shares by 157.9% (+33.5k shares)
Q4 2022
Avg closing price
$8.89
Price range
$7.78
-
$9.86
New holding (+21.2k shares)
Q3 2022
Avg closing price
$7.54
Price range
$6.29
-
$8.66
Sold -176k shares
Q2 2021
Avg closing price
$10.05
Price range
$8.46
-
$11.63
New holding (+176k shares)
Q1 2021
Avg closing price
$8.66
Price range
$6.87
-
$10.25
Sold -887k shares
Q4 2020
Avg closing price
$7.85
Price range
$6.59
-
$8.69
New holding (+887k shares)
Q3 2020
Avg closing price
$9.73
Price range
$7.40
-
$13.48
Sold -131k shares
Q2 2020
Avg closing price
$6.47
Price range
$4.09
-
$8.53
Sold 16.2% shares (-25.2k shares)
Q1 2020
Avg closing price
$6.05
Price range
$3.72
-
$7.57
Sold 58.9% shares (-224k shares)
Q4 2019
Avg closing price
$7.90
Price range
$6.19
-
$9.57
Sold 42.9% shares (-286k shares)
Q3 2019
Avg closing price
$5.67
Price range
$4.35
-
$6.56
Increased shares by 379.4% (+527k shares)
Q2 2019
Avg closing price
$6.37
Price range
$5.85
-
$6.99
Increased shares by 84.8% (+63.7k shares)
Q1 2019
Avg closing price
$7.22
Price range
$6.16
-
$8.19
Sold 67.0% shares (-153k shares)
Q4 2018
Avg closing price
$7.53
Price range
$6.01
-
$9.20
New holding (+228k shares)
Q3 2018
Avg closing price
$8.91
Price range
$8.05
-
$9.48
News about ADT Inc and Paul Tudor Jones II
Bayer announces positive topline results for NUBEQA? (darolutamide) from Phase III trial in men with metastatic hormone-sensitive prostate cancer (mHSPC)
WHIPPANY, N.J.--(BUSINESS WIRE)--The Phase III ARANOTE trial, investigating NUBEQA? (darolutamide) plus androgen deprivation therapy (ADT) in patients with m...
ADT Appoints William M. Lewis Jr. to the Company''s Board of Directors
BOCA RATON, Fla., June 16, 2022 (GLOBE NEWSWIRE) -- ADT Inc. (NYSE: ADT ), the most trusted brand in smart home and small business security, today announced ...